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Summary
 
Experimental autoimmune encephalomyelitis (EAE) is an inflammatory autoimmune disease of
the central nervous system which serves as a model for the human disease multiple sclerosis.
We demonstrate here that encephalitogenic T cells, transduced with a retroviral gene, con-
struct to express interleukin 4, and can delay the onset and reduce the severity of EAE when
adoptively transferred to myelin basic protein–immunized mice. Thus, T lymphocytes trans-
duced with retroviral vectors can deliver “regulatory cytokines” in a site-specific manner and
may represent a viable therapeutic strategy for the treatment of autoimmune disease.
 
I
 
nflammatory T cell responses to self antigens are impli-
cated in a number of autoimmune diseases (1–3). Modu-
lation of these responses by the systemic administration of
antiinflammatory cytokines such as IL-4 or transforming
growth factor 
 
b
 
 has shown therapeutic potential in animal
models of autoimmunity (4–6). However, side effects in-
herent in the systemic administration of cytokines necessi-
tate their local delivery (7). The therapeutic efficacy of tis-
sue-specific expression of IL-4 has recently been demonstrated
by transgenic expression in the nonobese diabetic mouse (8),
but thus far, no practical methods have been developed to
affect the local delivery of cytokines to the site of pathology.
Techniques for gene transfer in vivo, such as retrovirus-
mediated gene transduction, have the potential to deliver
immunosuppressive molecules in a site-specific manner,
thus limiting systemic effects. The feasibility of this ap-
proach has been recently demonstrated (9). In this study,
gene expression in vivo, required injection of high titer vi-
rus stocks directly to the site of inflammation, an impracti-
cal method for treating multifocal autoimmune diseases. An
alternative approach would be to use retrovirally trans-
duced T lymphocytes as delivery vehicles to target the
modulatory cytokines. This technique was originally de-
scribed in a model of demyelination experimental autoim-
mune neuritis in which a T cell line with specificity for the
P2 protein was transduced for the expression of nerve
growth factor; subsequent adoptive transfer ameliorated ex-
perimental autoimmune neuritis by mechanisms which are
not well understood (10). The studies described below re-
port our results of tissue-specific delivery of IL-4 to the
central nervous system (CNS) of mice with experimental
autoimmune encephalomyelitis (EAE).
 
Materials and Methods
 
Retroviral Constructs and Ecotropic Viral Production. 
 
The retro-
viral plasmid MSCV-(SD-)-IL-4-neo (11) contains the poliovirus
type 2 internal ribosome entry site sequence (12) between the
bacterial neomycin phosphotransferase gene (neo), conferring
neomycin resistance to eukaryotic cells, and the mouse IL-4 gene.
The proviral DNA is transcribed as a single polycistronic mRNA.
The internal ribosome entry site sequence allows for subsequent
translation of the two proteins. Ecotropic retrovirus was pro-
duced in the PHEONIX packaging cell line (G.P. Nolan, manu-
script in preparation). In brief, PHEONIX cells were plated at 2 
 
3
 
10
 
6
 
 cells/well in 6-cm plates and allowed to adhere overnight. The
cells were transfected with the IL-4-neo plasmid (10 
 
m
 
g/plate) by
CaCl
 
2
 
 transfection. Replication-defective retrovirus was har-
vested 48 hr after transfection, sterile filtered to remove nonad-
herent producer cells, and used to infect T cell hybrids.
 
T Cell Infections. 
 
Cells were grown to log phase, harvested,
and washed two times with PBS. Cells were resuspended to 2 
 
3
 
10
 
6
 
 cells/ml using retrovirus containing supernatant stocks. Poly-
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brene was added to a final concentration of 8 
 
m
 
g/ml. The cells
were placed in 6-well tissue culture plates (2 ml/plate) and centri-
fuged at 2,500 rpm for 90 min at 32
 
8
 
C in a tabletop centrifuge.
The cells were then incubated for a further 8 h at 37
 
8
 
C in a CO
 
2
 
incubator before the cells were washed and replated in fresh me-
dia without polybrene. After 48 h of culture to allow gene ex-
pression, transduced cells were selected by growth in the presence
of the neomycin analogue G418 (2 
 
m
 
g/ml) for 5–7 d.
 
Induction of EAE and Adoptive Transfer of Transduced T Cells.
 
EAE was induced by active immunization with mylein basic pro-
tein (MBP). In brief, MBP (200 
 
m
 
g/mouse final concentration)
in PBS was emulsified in an equal volume of CFA. (PL/J 
 
3
 
 SJL/
J)F1 mice (5 mice/group) were immunized subcutaneously at
four sites in the flanks, draining the axial and inguinal lymph
nodes (50 
 
m
 
l/site). Animals were also given an injection of the
coadjuvant pertussis toxin (200 ng/mouse) intravenously on the
day of immunization and 48 h later. Mice were scored daily for
clinical signs of EAE according to the following scale: 0, no clini-
cal disease; 1, flaccid tail; 2, single hind leg paralysis; 3, dual hind
leg paralysis; 4, fore limb paralysis; 5, moribund; 6, death. On day
9 or 10, mice were transferred 10
 
6
 
 of each cell type intravenously,
and were observed daily for clinical signs of EAE. Mice were
housed in the Stanford Department of Laboratory Animal Medi-
cine (Stanford, CA) under National Institutes of Health (NIH)
approved conditions.
 
Quantitation of IL-4 and IL-10 by ELISA. 
 
IL-4 and IL-10 were
quantitated using a sandwich ELISA. In brief, microtiter plates
were coated with primary antiinterleukin antibody overnight,
washed with PBS–Tween 20 and blocked with PBS–0.1% BSA.
Plates were then washed and samples were added to the wells. An
IL-4 or IL-10 standard was included in each assay for quantifica-
tion purposes. After a 2-h incubation, plates were washed and a
biotin-conjugated secondary antiinterleukin antibody was added.
The plates were then washed and an avidin–horseradish peroxi-
dase conjugate was added. A standard colormetric assay was then
performed by the addition of the peroxidase substrate 2,2
 
9
 
-azino-
bis (3
 
9
 
ethylbenzthiazoline-6-sulfonic acid). Color change was
measured in a microplate reader equipped with a 405-nm filter.
 
Results and Discussion
 
To test the concept of site-specific delivery of cytokines
by transduced T cells, the murine model of EAE was used. An
encephalitogenic, MBP-specific T cell hybridoma, G1.15H,
was used in these preliminary studies due to its transduction
efficiency. Adoptive transfer of the unmodified G1.15H to
naive (SJL/J 
 
3
 
 PL/J)F1 mice verified its EAE-inducing,
and thus CNS-homing, capability (Fig. 1). It was decided
to transduce this T cell line for expression of the IL-4 gene
since this cytokine has been demonstrated to be a mediator
in EAE regulation as evidenced by its role in the natural re-
covery from disease (13), experimental protection from dis-
ease after oral tolerance induction (14), and after immuni-
zation with altered peptide ligands of MBP (15).
After transduction of G1.15H with an IL-4–encoding
retrovirus and drug selection, the line was confirmed to se-
crete IL-4 by ELISA (Table 1). Subsequent limiting dilu-
tion cloning of these transduced hybrids yielded individual
lines secreting between 1 and 8 pg/ml IL-4/10
 
5
 
 cells (Table 1).
10 d after MBP immunization to induce EAE, (SJL/J 
 
3
 
PL/J)F1 mice were given transduced or control cells. Clin-
ical EAE was ameliorated by adoptive transfer of 10
 
6
 
 trans-
duced T cells secreting high levels of IL-4 (line N5). Dis-
ease onset for the IL-4 treatment group was delayed by 2 d
(
 
P
 
 
 
,
 
0.01 Student’s 
 
t
 
 test) and the average disease score was
significantly lower (
 
P
 
 
 
,
 
0.05) than an experimental group
Figure 1. Adoptive transfer of EAE using the MBP-specific T cell hy-
bridoma G1.15H. Three naive (PL/J 3 SJL/J)F1 mice were given 106
G1.15H cells intravenously on day 0. Each mouse (circles, squares, or trian-
gles, respectively) was scored daily for clinical signs of EAE as described in
Materials and Methods.
 
Table 1.
 
IL-4 and IL-10 Secreted by Cell Lines Used in this Study
 
Cell line Description IL-4 secreted IL-10 secreted
 
ng/ml/10
 
5
 
 cells
 
G1.15H MBP-specific, H-2s restricted T cell hybridoma 0 –
Bw.Z.4 T cell hybridoma fusion partner, IL-4 transduced 2.3 –
G1.15H.4.9 IL-4 transduced variant of G1.15H 2.5 –
G1.15H.N5 IL-4 transduced variant of G1.15H 7.9 –
G1.15H.marv1 IL-10–transduced variant of G1.15H – 255
Control IL-4– and IL-10–transduced cell lines were incubated overnight, and IL-4 and IL-10 in culture supernatants quantitated by ELISA as de-
scribed in Materials and Methods. 
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receiving cells transduced to express IL-10, or control mice
receiving untransduced cells or PBS (Fig. 2).
That amelioration of disease was due to local delivery of
IL-4 was supported by several experimental approaches. In
the first, mice that received T cells transduced to express
IL-4 were bled at various time points after cell transfer, and
serum IL-4 was determined by ELISA. No cytokine was
detected in the serum until day 24 after transfer, well after
initial recovery from disease. Serum IL-4 levels at this time
were low, ranging from 1.19 pg/ml to 2.53 pg/ml (Table
2). This finding indicates that disease remission was not due
to high systemic levels of IL-4. In a second experimental
approach, we verified the presence of transduced T cells in
the CNS at the time of disease amelioration by testing spi-
nal cord tissue from treated animals for retroviral-specific
IL-4 expression by reverse transcriptase PCR analysis. Ret-
roviral IL-4 transcription could be detected in the CNS of
treated animals 15 d after transfer of transduced T cells (data
not shown). The third experimental approach demon-
strated that amelioration of disease was dependent on T cell
homing to the CNS.
We reasoned that T cells transduced to express IL-4 that
could not recognize CNS antigens would be ineffective at
delivering IL-4 to the CNS. To test this hypothesis, addi-
tional transfer experiments were performed, using as con-
trols, transduced T cells expressing IL-4 but lacking antigen
specific TCR expression. In the first experiment, an IL-4–
expressing transductant of the hybridoma fusion partner
BW5147 was used as a control. Transfer of this cell line to
MBP-immunized mice had no effect on the disease course,
whereas transfer of an MBP-specific line, clone 4.9, secret-
ing low levels of IL-4 (matched to the fusion partner con-
trol) had a significant therapeutic effect (
 
P
 
 
 
,
 
0.05; data not
presented). In the second experimental approach, a TCR
negative variant of the IL-4–secreting disease ameliorating
N5 clone was used as a control. This line had significantly
less effect on the disease course (
 
P
 
 
 
,
 
0.05) when compared
to its TCR-expressing counterpart (Fig. 3).
The majority of approaches taken to control autoim-
mune disease result in deleterious side effects due to the
systemic administration of antiinflammatory agents. Our
findings indicate that the disease processes can be modu-
lated by the transfer of MBP-specific T cells which have
been retrovirally modified to express the antiinflammatory
cytokine IL-4. Disease amelioration was due to local, rather
than systemic, delivery of IL-4 as evidenced by the follow-
ing points. (
 
a
 
) Serum levels of IL-4 were undetectable at
the time of disease remission. (
 
b
 
) Retroviral-encoded IL-4
Figure 2. Adoptive transfer of T cells transduced to express IL-4 ame-
liorates MBP-induced EAE. Mice immunized to induce EAE were
treated with T cells transduced to express IL-4 (circles) or IL-10 (triangles),
untransduced T cells (diamonds), or PBS (squares), and observed for clinical
signs of EAE. Data are given as mean disease scores, and are representative
of the results of at least two independent experiments. Disease incidence
in all groups was 100%. *The mean disease score was statistically different
from all other groups, Student’s t test, P ,0.05.
 
Table 2.
 
Serum Levels of IL-4 at Various Times after Transfer
of T Cell Hybrids Transduced to Express IL-4
 
Serum IL-4 levels
Day 6 Day 13 Day 24
 
pg/ml
 
Mouse 1 n.d. n.d. 1.26
Mouse 2 n.d. n.d. 1.19
Mouse 3 n.d. n.d. 2.11
Mouse 4 n.d. n.d. 2.53
N5-transferred mice were bled from the tail vein on the indicated days
into heparinized tubes. Serum was obtained by centrifugation and tested
for IL-4 by ELISA as described in Materials and Methods. n.d., none
detected (lower limit of detection of ELISA 
 
5
 
 0.875 pg/ml).
Figure 3. Amelioration of EAE is dependent upon TCR expression by
IL-4–secreting T cells. MBP-immunized (PL/J 3 SJL/J)F1 mice (10
mice/group) were given 106 transduced TCR-positive, IL-4–secreting
N5 cells (circles) or TCR-negative, IL-4–secreting N5 cells (squares). Mice
were scored daily for clinical signs of EAE. Data are given as the mean
disease scores of those mice developing disease, and are representative of
the results of at least two independent experiments. Disease incidence was
90% in each group. *The mean disease score was statistically different
from all other groups, Student’s t test, P ,0.05. 
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expression could be detected in the CNS of treated mice.
(
 
c
 
) Disease amelioration was dependent upon antigen-spe-
cific T cell receptor expression on transduced T cells, indi-
cating that T cell antigen recognition and presumably “traf-
ficking” were necessary for delivery of cytokines.
The use of antigen-specific T cells, transduced to express
regulatory cytokines, selectively target antiinflammatory
molecules to the site of pathology represents a unique ther-
apeutic approach to the treatment of autoimmune disease.
T cells are advantageous since they are easily manipulated
and expanded in tissue culture before reintroduction into
the host. More importantly, the antigen specificity of T
cells allows them to home to depots of antigen in the body,
such as at inflammatory sites of autoimmune disease. This
has been demonstrated in the murine model of EAE where
MBP-specific T cells have been shown to traffic to the
CNS, both during the induction phase of disease as well as
during relapses in a relapsing-remitting model of EAE (16,
17). Results presented here demonstrate that a statistically
significant benefit can be observed when mice, immunized
to develop EAE, are given MBP-specific T cells retrovirally
transduced to express IL-4.
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